Business
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
INCHEON, Korea, March 15, 2026--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with G2GBIO, a company specializing in the development of sustained-release formulations, to develop novel assets based on G2GBIO’s proprietary microsphere technology.
About this update from Samsung Epis Holdings Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1270,"height":458,"url":"https://media.zenfs.com/en/business-wire.com/eda686b9e964695e643de799d0c5149c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QP5F.EvkK8OjIKBHZkjhuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eda686b9e964695e643de799d0c5149c","width":960,"height":346},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JHBJ8eHdGzxRebp.VgyqMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/eda686b9e964695e643de799d0c5149c","width":1200,"height":433}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO’s proprietary microsphere technology","length":174,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform","length":190,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":364,"olType":false},{"type":"text","content":"INCHEON, Korea, March 15, 2026--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with G2GBIO, a company specializing in the development of sustained-release formulations, to develop novel assets based on G2GBIO’s proprietary microsphere technology.","length":411,"tagName":"p"},{"type":"text","content":"Under the agreement, Samsung Bioepis will be given a full license right for the novel long-acting semaglutide asset, and an option to license another asset from G2GBIO. In addition, Samsung Bioepis will be given the first negotiation rights for the three other novel assets to be determined. Epis NexLab will be responsible for the co-development of the long-acting microsphere drug delivery platform using G2GBIO’s proprietary technology. The details of the financial terms remain confidential.","length":495,"tagName":"p"},{"type":"text","content...